 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || ABBV-176 / AbbVie
Review, Journal: Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies. (Pubmed Central) - Jan 31, 2023
Different strategies have been developed to target this receptor including modification of PRL peptides (Del1-9-G129R-hPRL, G129R-Prl), growth hormone receptor/prolactin receptor bispecific antibody antagonist, neutralizing antibody LFA102, an antibody-drug conjugate (ABBV-176) of the humanized antibody h16f (PR-1594804) and pyrrolobenzodiazepine dimer, a bispecific antibody targeting both PRLR and CD3, an in vivo half-life extended fusion protein containing PRLR antagonist PrlRA and albumin binding domain...Recently, using structure-based virtual screening, we identified a few antipsychotic drugs including penfluridol as a molecule that inhibits PRL-signaling to inhibit PDAC tumor progression. In this review, we will summarize the recent advances in the biology of this receptor in cancer and give an account of PRLR antagonist development for the treatment of cancer.
- | ABBV-176 / AbbVie
Journal, PARP Biomarker: ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition. (Pubmed Central) - Nov 4, 2021
In this review, we will summarize the recent advances in the biology of this receptor in cancer and give an account of PRLR antagonist development for the treatment of cancer. Collectively the efficacy and safety profile of ABBV-176 suggest it may be an effective therapy across a broad range of breast cancers and other cancer types where PRLR is expressed with the potential to combine with other therapeutics including PARP inhibitors.
- || ABBV-176 / AbbVie
Clinical, P1 data, Journal: A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors. (Pubmed Central) - Sep 12, 2021
P1
No responses were observed, although data were available from a small number of patients with variable tumor PRLR expression. This study was terminated after the dosing of 19 patients.
- | rolinsatamab talirine (ABBV-176) / AbbVie
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR) (clinicaltrials.gov) - Nov 29, 2018
P1, N=19, Terminated, Sponsor: AbbVie
This study was terminated after the dosing of 19 patients. N=120 --> 19 | Trial completion date: Mar 2020 --> Nov 2018 | Suspended --> Terminated | Trial primary completion date: Jun 2019 --> Nov 2018; Safety
- |||| rolinsatamab talirine (ABBV-176) / AbbVie
Trial suspension, Metastases: A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR) (clinicaltrials.gov) - Aug 31, 2018
P1, N=120, Suspended, Sponsor: AbbVie
N=120 --> 19 | Trial completion date: Mar 2020 --> Nov 2018 | Suspended --> Terminated | Trial primary completion date: Jun 2019 --> Nov 2018; Safety Recruiting --> Suspended
- | rolinsatamab talirine (ABBV-176) / AbbVie
Trial completion date, Metastases: A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR) (clinicaltrials.gov) - Apr 2, 2018
P1, N=100, Recruiting, Sponsor: AbbVie
Recruiting --> Suspended Trial completion date: Sep 2019 --> Mar 2020
- ||| rolinsatamab talirine (ABBV-176) / AbbVie
Enrollment open, Metastases: A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR) (clinicaltrials.gov) - Jul 23, 2017
P1, N=100, Recruiting, Sponsor: AbbVie
Trial completion date: Sep 2019 --> Mar 2020 Not yet recruiting --> Recruiting
- ||| rolinsatamab talirine (ABBV-176) / AbbVie
New P1 trial, Metastases: A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR) (clinicaltrials.gov) - May 9, 2017
P1, N=100, Not yet recruiting, Sponsor: AbbVie